Experimental combo aims to wipe out stubborn leukemia cells

NCT ID NCT04501939

Ongoing Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests whether adding cirmtuzumab to venetoclax can clear remaining leukemia cells in people with chronic lymphocytic leukemia (CLL) who still have detectable disease after standard treatment. Only 5 participants are enrolled, and the main goal is to see if the combination can make the cancer undetectable. The study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cirmtuzumab (Zilovertamab) and Venetoclax (VENCLEXTA)
What this could lead to: If successful, this combination could help clear remaining leukemia cells in patients who still have detectable disease after standard treatment, potentially delaying the need for further therapy.
What could go wrong: This is a very small, early-phase trial with only 5 participants, so results may not apply to a broader population. Side effects from the drug combination are possible, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

UCSD Koman Family Outpatient Pavilion

San Diego, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.